Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

Recruiting

Phase 2

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After SurgeryUsing Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

Sponsor:

National Cancer Institute (NCI)

Code:

NCT05111574

Conditions

Anal Melanoma

Bladder Melanoma

Cervical Melanoma

Esophageal Melanoma

Gallbladder Melanoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Bone Scan

Cabozantinib S-malate

Computed Tomography

Echocardiography

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-25. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-03-20.